Equities

Nanoform Finland Oyj

Nanoform Finland Oyj

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)1.62
  • Today's Change-0.018 / -1.10%
  • Shares traded31.24k
  • 1 Year change-16.06%
  • Beta0.9565
Data delayed at least 15 minutes, as of Sep 23 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of EUR
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments476976
Total Receivables, Net1.182.091.25
Total Inventory0.220.01--
Prepaid expenses0.160.080.09
Other current assets, total000
Total current assets497177
Property, plant & equipment, net272720
Goodwill, net------
Intangibles, net0.610.380.29
Long term investments1.481.922.00
Note receivable - long term0.290.290.29
Other long term assets0--0
Total assets7810199
LIABILITIES
Accounts payable------
Accrued expenses3.284.624.22
Notes payable/short-term debt000
Current portion long-term debt/capital leases1.942.232.82
Other current liabilities, total0.770.681.12
Total current liabilities5.987.538.17
Total long term debt5.205.906.69
Total debt7.148.129.51
Deferred income tax------
Minority interest------
Other liabilities, total0----
Total liabilities111315
SHAREHOLDERS EQUITY
Common stock0.080.080.08
Additional paid-in capital------
Retained earnings (accumulated deficit)678784
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total00--
Total equity678784
Total liabilities & shareholders' equity7810199
Total common shares outstanding787873
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.